Blurbs

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Pfizer (PFE)

Analysts fell to the sidelines weighing in on Neurocrine (NBIXResearch Report) and Pfizer (PFEResearch Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Neurocrine (NBIX)

SVB Securities analyst Marc Goodman maintained a Hold rating on Neurocrine on June 29 and set a price target of $100.00. The company’s shares closed last Friday at $99.25.

According to TipRanks.com, Goodman is a 1-star analyst with an average return of -2.5% and a 43.5% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Opthea Limited Sponsored ADR, and Amylyx Pharmaceuticals Inc.

Currently, the analyst consensus on Neurocrine is a Moderate Buy with an average price target of $110.00, implying a 12.8% upside from current levels. In a report issued on June 28, RBC Capital also maintained a Hold rating on the stock with a $93.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Pfizer (PFE)

In a report issued on June 30, David Risinger from SVB Securities maintained a Hold rating on Pfizer, with a price target of $55.00. The company’s shares closed last Friday at $52.31.

According to TipRanks.com, Risinger is a 2-star analyst with an average return of 0.2% and a 50.0% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Horizon Therapeutics, and Theravance Biopharma.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $58.64 average price target, which is a 12.7% upside from current levels. In a report issued on June 28, J.P. Morgan also maintained a Hold rating on the stock with a $57.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NBIX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos